<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000823.v1.p1" parentStudy="phs000823.v1.p1" createDate="2014-10-22" modDate="2014-10-22">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Stacey Gabriel</td><td>Broad Institute, Cambridge, MA, USA</td></tr>
		<tr><td>Co-Investigator</td><td>Hensin Tsao</td><td>Massachusetts General Hospital, Boston, MA, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Discovery of Novel Melanoma Predisposing Mutations by Exome Sequencing</StudyNameEntrez>
	<StudyNameReportPage>Discovery of Novel Melanoma Predisposing Mutations by Exome Sequencing</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case Set</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Melanoma risk shows clear heritability, but the inherited genetic factors remain largely unknown. Rare high risk mutations in CDKN2A, CDK4, BAP1 and TERT have been described but these variants, in aggregate, account for less than 50% of the kindreds reporting a family history of melanoma. This project will seek to identify new genes which may confer melanoma susceptibility. Identifying melanoma predisposing mutations can provide new biological insights and may impact important clinical decision making regarding treatment, surveillance and preventive approaches. Hereditary melanoma patients (defined as those individuals with multiple primary melanomas and those patients with a family history of melanoma) were collected from melanoma clinics at the Massachusetts General Hospital in Boston and the A. Sygrous Hospital in Athens, Greece.</p> <p>All exome sequencing was performed at the Broad Institute of Harvard and MIT; samples sequence capture was performed using Agilent SureSelect Human All Exon Kit v2 and sequencing was performed on an Illumina HiSeq 2000 or 2500.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Inclusion criteria<br/> Individuals &#62;18 years of age with<br/> <ol> <li>3 or more primary cutaneous melanomas<br/> OR<br/> (example includes an individual with 3 primary melanomas)<br/> </li> <li>at least one primary cutaneous melanoma and &#8805;1 affected 1st degree relative with melanoma <br/> OR<br/> (example includes an individual with 1 melanoma and a brother with melanoma)<br/> </li> <li>at least one primary cutaneous melanoma and &#8805;2 affected relatives on one side of the lineage<br/> (example includes an individual with 1 melanoma and two maternal uncles with melanoma) </li> </ol> </p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Melanoma"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Stacey Gabriel</AttName>
			<Institution>Broad Institute, Cambridge, MA, USA</Institution>
		</Header>
		<Header title="Co-Investigator">
			<AttName>Hensin Tsao</AttName>
			<Institution>Massachusetts General Hospital, Boston, MA, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="DS-CA" longName="Disease-Specific (Cancer)"/>
		<ConsentGroup groupNum="2" shortName="GRU" longName="General Research Use"/>
		<ConsentGroup groupNum="3" shortName="DS-UM-NPU" longName="Disease-Specific (Uveal Melanoma, NPU)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NHGRI</DacName>
      <DacFullName>National Human Genome Research Institute</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000823.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>12</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000823.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000823.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Disease-Specific (Cancer)</ConsentName>
        <ConsentAbbrev>DS-CA</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Cancer.
All data is to be used for the research on the causes and development of cancer</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
      <ParticipantSet groupNum-REF="2">
        <ConsentName>General Research Use</ConsentName>
        <ConsentAbbrev>GRU</ConsentAbbrev>
        <UseLimitation>Use of the data is limited only by the terms of the model Data Use Certification.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
      <ParticipantSet groupNum-REF="3">
        <ConsentName>Disease-Specific (Uveal Melanoma, NPU)</ConsentName>
        <ConsentAbbrev>DS-UM-NPU</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Uveal Melanoma.
Use of the data is limited to not-for-profit organizations.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
